文献速递口腔修复与种植口腔颌面外科

接受抗骨吸收药物治疗的牙种植患者中药物相关性颌骨坏死:范围综述

Medication-Related Osteonecrosis of the Jaws in Patients on Antiresorptive Medication With Dental Implants. A Scoping Review.
PubMed 文献 · Clin Oral Implants Res · 2025-06-18

该范围综述按PRISMA-ScR的PCC框架,于2024年4月13日检索PubMed、Embase和Cochrane Library,纳入28项研究共76例患者、215枚种植体(低剂量抗骨吸收药物154枚,高剂量61枚)。证据不足以确认累积抗骨吸收药物剂量与种植体相关药物相关性颌骨坏死的关联,未识别出特定危险因素。

要点

  • 共纳入28项研究、76例患者、215枚种植体,其中低剂量抗骨吸收药物154枚、高剂量61枚。
  • 证据不足以确认累积抗骨吸收药物剂量与种植体相关药物相关性颌骨坏死的关联。
  • 未识别出特定危险因素,作者强调需标准化报告抗骨吸收药物类型、剂量、疗程和间隔。

核心结论

  • 证据不足以确认累积抗骨吸收药物剂量与种植体相关药物相关性颌骨坏死的关联。
  • 未识别出特定危险因素,作者强调需标准化报告抗骨吸收药物类型、剂量、疗程和间隔以促进全面风险评估。

研究设计与样本

  • 范围综述,遵循PRISMA-ScR的PCC框架,比较发生种植体相关药物相关性颌骨坏死的抗骨吸收药物治疗患者与未发生者。
  • 于2024年4月13日在PubMed、Embase和Cochrane Library进行系统检索,两名评价者独立筛选和提取数据,第三名评价者解决分歧。
  • 共纳入28项研究,涉及76例患者、215枚种植体,其中低剂量抗骨吸收药物154枚、高剂量61枚。

主要发现

  • 15项研究报告了低剂量抗骨吸收药物患者发生药物相关性颌骨坏死,4项研究报告了高剂量抗骨吸收药物患者发生药物相关性颌骨坏死。
  • 共纳入28项研究、76例患者、215枚种植体,低剂量抗骨吸收药物154枚、高剂量61枚。

临床怎么用

  • 在高剂量抗骨吸收药物或长期低剂量抗骨吸收药物患者中,种植治疗应限于专科中心,直至出现循证指南。

局限性

  • 证据不足以确认累积抗骨吸收药物剂量与种植体相关药物相关性颌骨坏死的关联。
  • 未识别出特定危险因素,强调需标准化报告抗骨吸收药物类型、剂量、疗程和间隔。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Patients receiving antiresorptive medication (AR) for osteoporosis or cancer are at risk of medication-related osteonecrosis of the jaws (MRONJ), especially after surgical procedures. Dental implant (DI) placement in high-dose AR (HDAR) patients is widely discouraged, and thorough counseling is recommended for low-dose AR (LDAR) patients. However, data on the role of AR type, dose, and duration remain limited. This review evaluates MRONJ associated with DIs, focusing on AR type and accumulated dose, and identifies local and systemic risk factors. MATERIALS AND METHODS: This review follows the PCC framework for PRISMA-ScR, comparing patients on AR who developed DI-related MRONJ to those who did not, based on the available clinical evidence. A systematic search was conducted on April 13, 2024, in PubMed, Embase, and Cochrane Library. Two reviewers independently screened and extracted data; a third reviewer resolved disagreements. Data extraction included demographics, primary disease, AR type, dose, treatment duration, DI location, and MRONJ details. RESULTS: Of 2201 articles, 28 studies were included involving 76 patients with 215 DI (154 in LDAR, 61 in HDAR). The development of MRONJ was reported in 15 studies involving LDAR and four studies on HDAR. CONCLUSIONS: Evidence was insufficient to confirm an association between accumulated AR dose and MRONJ associated with DIs. No specific risk factors were identified, emphasizing the need for standardized reporting on AR type, dosage, treatment duration, and intervals to facilitate comprehensive risk assessment. Until evidence-based guidelines emerge, DI therapy in HDAR or long-term LDAR patients should be limited to specialized centers.

来源:Clin Oral Implants Res,查看原文。版权归原作者所有。

引用

  1. Andersen SWM, Hindocha NV, Poulsen I, et al. Medication-Related Osteonecrosis of the Jaws in Patients on Antiresorptive Medication With Dental Implants. A Scoping Review. Clin Oral Implants Res. 2025. PMID: 40531168. doi:10.1111/clr.14453

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。